Technologies for the discovery and development of drugs targeting challenging membrane proteins, including GPCRs and ion channels.

Innovative medicines to address unmet medical needs in central nervous system disorders.

Development of drugs for the treatment of atrial fibrillation.

First-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases.

Development of drugs for neuropathic pain and other indications with unmet medical need.

Small molecule therapeutics for the treatment of Alzheimer’s disease and other CNS diseases.

Innovative drug therapies for the treatment of severe diseases that affect the central nervous system.

Discovering, developing, manufacturing and delivering innovative human therapeutics.

Discovery, development and commercialization of therapeutics for rare diseases and vaccines.

Develops medicines that treat intractable diseases by silencing the genes that cause them.

Discovery and development of novel targeted therapies in inflammation/immunology and oncology.

Developing new drugs to treat rare CNS disorders.

Developing novel therapies for CNS conditions that have limited treatment options.

Novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.

Discovery, development and delivery of innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases.

Developing novel ion channel modulators for patients with underserved CNS disorders.

Targeted therapeutics and immune-oncology products for cancer patients.

Developing drugs for the treatment of inflammatory diseases, including acute pancreatitis and COVID-19 pneumonia.

Small-molecule therapeutics for the treatment of neurodegenerative and rare diseases.

New medicines for a broad range of diseases.

Therapies to restore the brain’s natural rhythms for a range of neurological and rare genetic diseases.

Discovery of ion channel modulators for treating aggressive, invasive and metastatic cancer forms.

Discovery and development of new therapies for people suffering from neuroscience diseases.

Developing gene therapies for the treatment of neurological diseases.

Development of autoimmune therapeutics.

Develops, manufactures, and commercializes pharmaceuticals.

Develops novel approach to gene therapy for people living with pediatric CNS diseases.

Acquisition, development and commercialization of patient-centric therapies.

Research and development of novel therapies for the treatment of respiratory diseases.

Development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions.

Addresses unmet medical needs in inflammation disorders, especially in respiratory and dermatology therapies and also oncology.

Precision medicine product candidates for patients with kidney diseases.

Drug discovery contract research services.

Technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets.

Develops next generation immunotherapies.

Delivery of treatments for immunological and neurological diseases.

Discovery, development and manufacturing of pharmaceutical products.

Therapeutic candidates against ion channels and GPCR proteins.

Discovery, development and delivery of treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.

Pharmacological assays based on electrophysiological recordings.

Discovery and development of novel therapeutics for neuromuscular diseases.

Development of a new therapy for the treatment of serious conditions including cough, itch, pain and inflammation.

Drug development programs in neuropathic pain and oncology.

R&D-oriented company developing and manufacturing pharmaceutical products.

Development and commercialization of therapies to restore the innate mucosal surface defense of the lung.

Development of a new oral anti-diabetic agent.

Development of therapies for patients affected by CNS disorders characterized by neuronal imbalance.

Development of precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases.

Developing proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system.

Developing non-opioid therapeutics that relieve chronic pain.

Developing differentiated products through cutting-edge science and strategic partnerships.

Developing novel therapeutics for children suffering from SCN2A mutations.

Research and development of novel, disease-modifying compounds for the treatment of autism and epilepsy.

Development of next-generation therapeutics.

Discovery, development and delivery of innovative treatments for rare disease patients.

Peptide blockers for ion channels.

Discovery and development of pharmaceutical products.

Therapeutics for the treatment of hypersensitivity disorders such as chronic cough, itch and pain.

Development and commercialization of novel therapeutics for the treatment of rare diseases.

Development of novel trageted treatments for cancer.

Development of new transformative medicines for patients with unmet medical need.

Development of novel treatments of severe genetic diseases.

Developing a new class of potentially transformative mRNA medicines.

Development of innovative drugs with superior potency, target selectivity and safety.

Research and development of novel drug, agrichemicals, and biochemicals.

Invests in scientific innovation to create transformative medicines for people with serious diseases.

Developing and commercializing a new generation of medicines for anxiety, depression and other CNS disorders.

Developing innovative therapeutics to improve the lives of patients with neurological disorders.

Developing birth control options that are hormone-free, safe, easy to use and effective.